Article thumbnail

Telaprevir/boceprevir era: From bench to bed and back

By Qiuwei Pan, Maikel Peppelenbosch, Harry Janssen and Robert Knegt

Abstract

textabstractHepatitis C virus (HCV) infects approximately 200 million people worldwide. Interferon-based therapies have dominated over the past two decades. However, the overall response rates remain suboptimal. Thanks to the tremendous effort from both academia and industry, two serine protease inhibitors telaprevir and boceprevir for treating chronic hepatitis C have finally reached the clinic. Although these compounds are only approved for combination use with interferon and ribavirin in genotype 1 HCV infected chronic patients, the management of HCV patients however is now evolving incredibly. Here, we overviewed a series of landmark studies, regarding the clinical development of telaprevir and boceprevir. We discussed the mechanism-ofaction of telaprevir/boceprevir and their potential application in HCV-positive liver transplantation patients. We further emphasized some emerging concerns with perspective of further development in this field

Year: 2012
DOI identifier: 10.3748/wjg.v18.i43.6183
OAI identifier:
Provided by: NARCIS
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.loc.gov/mods/v3 (external link)
  • http://repub.eur.nl/oai (external link)
  • http://hdl.handle.net/1765/745... (external link)
  • http://hdl.handle.net/1765/745... (external link)
  • http://repub.eur.nl/pub/74519/... (external link)
  • http://repub.eur.nl/pub/74519/... (external link)

  • To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

    Suggested articles